By Kelly Cloonan
Shares of Skye Bioscience rose after the company announced promising preclinical data for a drug combination including its new CB1 antibody nimacimab.
The stock was up 60% to $2.09 Tuesday. Shares have lost 84% over the past 12 months.
The biotechnology company said nimacimab combined with tirzepatide resulted in greater than 30% weight loss for mice in a diet-induced obesity model over 25 days.
Nimacimab alone demonstrated 24% weight loss, comparable with monlunabant and tirzepatide alone, the company said.
Chief Executive Punit Dhillon said data supports the company's belief that its antibody approach can provide meaningful efficacy without the risk of unwanted neuropsychiatric side effects that come with small molecule CB1 inhibitors like monlunabant.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 15, 2025 12:31 ET (16:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。